{
  "api_version": "1",
  "request": {
    "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Caplacizumab",
    "query": {
      "intervention": "Caplacizumab"
    },
    "page_size": 10
  },
  "pagination": {
    "page": 1,
    "page_size": 10,
    "total_count": 6,
    "total_pages": 1,
    "next_page_url": null,
    "previous_page_url": null
  },
  "source": "remote",
  "last_synced_at": "2026-09-08T00:04:13.557Z",
  "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.",
  "notes": [
    "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.",
    "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.",
    "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees."
  ],
  "trials": [
    {
      "nct_id": "NCT05468320",
      "title": "Caplacizumab and Immunosuppressive Therapy Without Firstline Therapeutic Plasma Exchange in Adults With Immune-mediated Thrombotic Thrombocytopenic Purpura",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Thrombotic Thrombocytopenic Purpura"
      ],
      "interventions": [
        {
          "name": "Caplacizumab",
          "type": "DRUG"
        },
        {
          "name": "Corticosteroids",
          "type": "DRUG"
        },
        {
          "name": "anti-CD20 antibody",
          "type": "BIOLOGICAL"
        }
      ],
      "intervention_types": [
        "DRUG",
        "BIOLOGICAL"
      ],
      "sponsor": "Sanofi",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "80 Years",
        "sex": "ALL",
        "summary": "18 Years to 80 Years"
      },
      "enrollment_count": 51,
      "start_date": "2022-11-21",
      "completion_date": "2024-12-26",
      "has_results": true,
      "last_update_posted_date": "2025-12-30",
      "last_synced_at": "2026-09-08T00:04:13.557Z",
      "location_count": 4,
      "location_summary": "Birmingham, Alabama • Baltimore, Maryland • Durham, North Carolina + 1 more",
      "locations": [
        {
          "city": "Birmingham",
          "state": "Alabama"
        },
        {
          "city": "Baltimore",
          "state": "Maryland"
        },
        {
          "city": "Durham",
          "state": "North Carolina"
        },
        {
          "city": "Columbus",
          "state": "Ohio"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT05468320"
    },
    {
      "nct_id": "NCT01151423",
      "title": "Study to Assess Efficacy and Safety of Anti-von Willebrand Factor (vWF) Nanobody in Patients With Acquired Thrombotic Thrombocytopenic Purpura (aTTP)",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Acquired Thrombotic Thrombocytopenic Purpura"
      ],
      "interventions": [
        {
          "name": "Caplacizumab",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Placebo",
          "type": "BIOLOGICAL"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL"
      ],
      "sponsor": "Ablynx, a Sanofi company",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 75,
      "start_date": "2011-01",
      "completion_date": "2014-03",
      "has_results": true,
      "last_update_posted_date": "2023-04-04",
      "last_synced_at": "2026-09-08T00:04:13.557Z",
      "location_count": 13,
      "location_summary": "Los Angeles, California • Washington D.C., District of Columbia • Atlanta, Georgia + 10 more",
      "locations": [
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "Washington D.C.",
          "state": "District of Columbia"
        },
        {
          "city": "Atlanta",
          "state": "Georgia"
        },
        {
          "city": "St Louis",
          "state": "Missouri"
        },
        {
          "city": "New York",
          "state": "New York"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01151423"
    },
    {
      "nct_id": "NCT02553317",
      "title": "Phase III Trial With Caplacizumab in Patients With Acquired Thrombotic Thrombocytopenic Purpura",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Acquired Thrombotic Thrombocytopenic Purpura"
      ],
      "interventions": [
        {
          "name": "Caplacizumab",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Placebo",
          "type": "BIOLOGICAL"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL"
      ],
      "sponsor": "Ablynx, a Sanofi company",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 145,
      "start_date": "2015-11",
      "completion_date": "2017-08",
      "has_results": true,
      "last_update_posted_date": "2023-04-05",
      "last_synced_at": "2026-09-08T00:04:13.557Z",
      "location_count": 19,
      "location_summary": "Birmingham, Alabama • Los Angeles, California • Atlanta, Georgia + 15 more",
      "locations": [
        {
          "city": "Birmingham",
          "state": "Alabama"
        },
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "Atlanta",
          "state": "Georgia"
        },
        {
          "city": "Boston",
          "state": "Massachusetts"
        },
        {
          "city": "St Louis",
          "state": "Missouri"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02553317"
    },
    {
      "nct_id": "NCT02878603",
      "title": "Follow-up Study for Patients Who Completed Study ALX0681-C301 (Post-HERCULES)",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Acquired Thrombotic Thrombocytopenic Purpura"
      ],
      "interventions": [
        {
          "name": "Caplacizumab",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Standard of Care",
          "type": "OTHER"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL",
        "OTHER"
      ],
      "sponsor": "Sanofi",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 104,
      "start_date": "2016-10-06",
      "completion_date": "2020-10-23",
      "has_results": true,
      "last_update_posted_date": "2022-03-28",
      "last_synced_at": "2026-09-08T00:04:13.557Z",
      "location_count": 8,
      "location_summary": "St Louis, Missouri • Valhalla, New York • Durham, North Carolina + 5 more",
      "locations": [
        {
          "city": "St Louis",
          "state": "Missouri"
        },
        {
          "city": "Valhalla",
          "state": "New York"
        },
        {
          "city": "Durham",
          "state": "North Carolina"
        },
        {
          "city": "Columbus",
          "state": "Ohio"
        },
        {
          "city": "Oklahoma City",
          "state": "Oklahoma"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02878603"
    },
    {
      "nct_id": "NCT06358703",
      "title": "Impact of Acute ITTP Therapies on Long Term Neurologic and Cognitive Outcomes in ITTP Survivors",
      "overall_status": "NOT_YET_RECRUITING",
      "study_type": "OBSERVATIONAL",
      "phases": [],
      "conditions": [
        "Immune Thrombotic Thrombocytopenia"
      ],
      "interventions": [
        {
          "name": "Caplacizumab",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "US Thrombotic Microangiopathy Alliance",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 116,
      "start_date": "2024-12",
      "completion_date": "2028-05",
      "has_results": false,
      "last_update_posted_date": "2024-11-13",
      "last_synced_at": "2026-09-08T00:04:13.557Z",
      "location_count": 1,
      "location_summary": "Groveport, Ohio",
      "locations": [
        {
          "city": "Groveport",
          "state": "Ohio"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT06358703"
    },
    {
      "nct_id": "NCT03172208",
      "title": "Caplacizumab Single and Multiple Dose Study in Healthy Japanese and White Subjects.",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Healthy Volunteers"
      ],
      "interventions": [
        {
          "name": "Caplacizumab Dose 1 iv (single-dose)",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Caplacizumab Dose 2 iv (single-dose)",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Caplacizumab Dose 2 sc (single-dose)",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Caplacizumab Dose 2 sc (multiple-dose)",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Placebo iv (single-dose)",
          "type": "OTHER"
        },
        {
          "name": "Placebo sc (single-dose)",
          "type": "OTHER"
        },
        {
          "name": "Placebo sc (multiple-dose)",
          "type": "OTHER"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL",
        "OTHER"
      ],
      "sponsor": "Ablynx, a Sanofi company",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "65 Years",
        "sex": "ALL",
        "summary": "18 Years to 65 Years"
      },
      "enrollment_count": 60,
      "start_date": "2017-06-05",
      "completion_date": "2017-10-19",
      "has_results": false,
      "last_update_posted_date": "2017-11-14",
      "last_synced_at": "2026-09-08T00:04:13.557Z",
      "location_count": 1,
      "location_summary": "Glendale, California",
      "locations": [
        {
          "city": "Glendale",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03172208"
    }
  ]
}